Physician profile
Jackson Payne
NPI 1194407379
$490.64
in general payments reported to CMS, 2019-2025
16 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $237 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $74.06 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Esperion Therapeutics, INC. | $61.34 | 2024-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $54.56 | 2025 | Amvuttra |
| Baxter Healthcare | $41.30 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $32.67 | 2024-2025 | Wainua, Farxiga |
| Atricure, INC. | $30.19 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Merck Sharp & Dohme LLC | $28.76 | 2024-2025 | Verquvo |
| Edwards Lifesciences Corporation | $27.43 | 2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $18.81 | 2025 | |
| Boston Scientific Corporation | $18.72 | 2025 | Ranger |
| Midsouth Orthopedics INC. | $18.52 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $17.67 | 2024 | Arcalyst |
| Novo Nordisk INC | $17.46 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $16.86 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $16.73 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.